David Boulate1, Fréderic Perros2, Peter Dorfmuller3, Jennifer Arthur-Ataam4, Julien Guihaire1, Lilia Lamrani5, Benoit Decante1, Marc Humbert6, Saadia Eddahibi2, Philippe Dartevelle7, Elie Fadel7, Olaf Mercier8. 1. Laboratoire de Recherche Chirurgicale, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson. 2. INSERM U999, Labex LERMIT, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson. 3. Laboratoire de Recherche Chirurgicale, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson; INSERM U999, Labex LERMIT, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson; Service d'Anatomopathologie, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson; Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France. 4. Laboratoire de Recherche Chirurgicale, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson; INSERM U999, Labex LERMIT, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson. 5. Service de Chirurgie Thoracique, Vasculaire et de Transplantation Cardiopulmonaire, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson. 6. INSERM U999, Labex LERMIT, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson; Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France; Service de Pneumologie et Réanimation Respiratoire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France. 7. Laboratoire de Recherche Chirurgicale, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson; INSERM U999, Labex LERMIT, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson; Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France; Service de Chirurgie Thoracique, Vasculaire et de Transplantation Cardiopulmonaire, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson. 8. Laboratoire de Recherche Chirurgicale, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson; INSERM U999, Labex LERMIT, Hypertension Artérielle Pulmonaire: Physiopathologie et Innovation Thérapeutique, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson; Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France; Service de Chirurgie Thoracique, Vasculaire et de Transplantation Cardiopulmonaire, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson. Electronic address: o.mercier@ccml.fr.
Abstract
BACKGROUND: Pulmonary microvascular disease (PMD) develops in both occluded and non-occluded territories in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and may cause persistent pulmonary hypertension after pulmonary endarterectomy. Endothelin-1 (ET-1) and interleukin-6 (IL-6) are potential PMD severity biomarkers, but it remains unknown whether they are related to occluded or non-occluded territories. We assessed PMD and ET-1/IL-6 gene expression profiles in occluded and non-occluded territories with and without chronic lung reperfusion in an animal CTEPH model. METHODS: Chronic PH was induced in 10 piglets by left pulmonary artery (PA) ligation followed by weekly embolization of right lower lobe arteries with enbucrilate tissue adhesive for 5 weeks. At Week 6, 5 of 10 animals underwent left PA reperfusion. At Week 12, animals with and without reperfusion were compared with sham animals (n = 5). Hemodynamics, lung morphometry and ET-1/IL-6 gene expression profiles were assessed in the left lung (LL, occluded territories) and right upper lobe (RUL, non-occluded territories). RESULTS: At Week 12, mean PA pressure remained elevated without reperfusion (29.0 ± 2.8 vs 27.0 ± 1.1 mm Hg, p = 0.502), but decreased after reperfusion (30.0 ± 1.5 vs 20.5 ± 1.7 mm Hg, p = 0.013). Distal media thickness in the LL and RUL PAs and systemic vasculature to the LL were significantly lower in the reperfused and sham groups compared with the non-reperfused group. PMD progression was related to ET-1 and IL-6 gene expression in the RUL and to the ET-A/ET-B gene expression ratio in the LL. CONCLUSIONS: PMD regressed in occluded and non-occluded territories after lung reperfusion. Changes in ET-1 and IL-6 gene expression were associated with PMD in non-occluded territories.
BACKGROUND:Pulmonary microvascular disease (PMD) develops in both occluded and non-occluded territories in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and may cause persistent pulmonary hypertension after pulmonary endarterectomy. Endothelin-1 (ET-1) and interleukin-6 (IL-6) are potential PMD severity biomarkers, but it remains unknown whether they are related to occluded or non-occluded territories. We assessed PMD and ET-1/IL-6 gene expression profiles in occluded and non-occluded territories with and without chronic lung reperfusion in an animal CTEPH model. METHODS: Chronic PH was induced in 10 piglets by left pulmonary artery (PA) ligation followed by weekly embolization of right lower lobe arteries with enbucrilate tissue adhesive for 5 weeks. At Week 6, 5 of 10 animals underwent left PA reperfusion. At Week 12, animals with and without reperfusion were compared with sham animals (n = 5). Hemodynamics, lung morphometry and ET-1/IL-6 gene expression profiles were assessed in the left lung (LL, occluded territories) and right upper lobe (RUL, non-occluded territories). RESULTS: At Week 12, mean PA pressure remained elevated without reperfusion (29.0 ± 2.8 vs 27.0 ± 1.1 mm Hg, p = 0.502), but decreased after reperfusion (30.0 ± 1.5 vs 20.5 ± 1.7 mm Hg, p = 0.013). Distal media thickness in the LL and RUL PAs and systemic vasculature to the LL were significantly lower in the reperfused and sham groups compared with the non-reperfused group. PMD progression was related to ET-1 and IL-6 gene expression in the RUL and to the ET-A/ET-B gene expression ratio in the LL. CONCLUSIONS:PMD regressed in occluded and non-occluded territories after lung reperfusion. Changes in ET-1 and IL-6 gene expression were associated with PMD in non-occluded territories.
Authors: Sébastien Bonnet; Steeve Provencher; Christophe Guignabert; Frédéric Perros; Olivier Boucherat; Ralph Theo Schermuly; Paul M Hassoun; Marlene Rabinovitch; Mark R Nicolls; Marc Humbert Journal: Am J Respir Crit Care Med Date: 2017-03-01 Impact factor: 21.405
Authors: George A Alba; Deepak Atri; Sriranjani Darbha; Inderjit Singh; Victor F Tapson; Michael I Lewis; Hyung J Chun; Yen-Rei Yu; Bradley A Maron; Sudarshan Rajagopal Journal: Curr Cardiol Rep Date: 2021-08-19 Impact factor: 2.931
Authors: Frédéric Perros; Maria-Rosa Ghigna; Fanny Loisel; Denis Chemla; Benoit Decante; Vincent de Montpreville; David Montani; Marc Humbert; Elie Fadel; Olaf Mercier; David Boulate Journal: Biomedicines Date: 2020-11-11
Authors: Mitchel J Colebank; M Umar Qureshi; Sudarshan Rajagopal; Richard A Krasuski; Mette S Olufsen Journal: Am J Physiol Heart Circ Physiol Date: 2021-06-18 Impact factor: 5.125
Authors: Ashley Mulchrone; Heidi B Kellihan; Omid Forouzan; Timothy A Hacker; Melissa L Bates; Christopher J Francois; Naomi C Chesler Journal: Front Cardiovasc Med Date: 2019-01-09